Bal Pharma poised to strengthen its position in diabetes segment

28 Sep 2021 Evaluate

Bal Pharma is further strengthening its market leading position in Gliclazide (API) with higher capacity utilization at the existing facility, and the streamlining of new facility that commenced production of Gliclazide in September 2020. Gliclazide, API is a sulfonyl urea component used for treating type 2 Diabetes, has been an important contributor in the company’s earnings.

Bal Pharma, incorporated in 1987 is engaged in the business interest in area of manufacturing API, finished formulations, ayurvedic and research and development. It is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.

Bal Pharma Share Price

68.50 -0.69 (-1.00%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×